Serum C‐reactive protein levels predict survival in hepatocellular carcinoma

Sakae Nagaoka(Kurume University), Michio Sata(Kurume University), Takuji Torimura(Omuta hospital), Junichi Kurogi(Kurume University), Jun Akiba(Kurume University), Junji Akiyoshi(Kurume University), Takafumi Yoshida(Kurume University), Takashi Niizeki(Kurume University), Masamichi Kojiro(Yanagawa Rehabilitation Hospital), Tsutomu Imaizumi(Rohto Pharmaceutical (Japan)), Nobuyoshi Tajiri(Kurume University), Kinya Inoue(University Hospital Kyoto Prefectural University of Medicine), Hisashi Adachi(Kurume University), Hironori Koga(Kurume University)
Liver International
August 15, 2007
10.1111/j.1478-3231.2007.01550.x
Cited by 102

Related Papers

Transplanted cord blood–derived endothelial precursor cells augment postnatal neovascularization
|Journal of Clinical Investigation|2000|892
Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial
|Gut|2019|732
Therapeutic effects of restricted diet and exercise in obese patients with fatty liver
|Journal of Hepatology|1997|614
Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH‐HCC guidelines) 2019 update
|Hepatology Research|2019|539
Hepatitis C Virus Down-Regulates Insulin Receptor Substrates 1 and 2 through Up-Regulation of Suppressor of Cytokine Signaling 3
|American Journal Of Pathology|2004|536